China-based WuXi Biologics (Cayman) Inc. priced its IPO at the top end of its guidance, Reuters reported, citing a source.

The company priced the issue of 193 million shares at HK$20.60 apiece to raise about HK$3.98 billion.

WuXi provides a comprehensive, integrated and customized range of services for the discovery, development and manufacturing of biologics.